Replies to post #186658 on Biotech Values

[dewophile]

BMY
I don't think Bristol is that popular a stock on this board, and it isn't exactly cheap when viewed on an earnings basis, but you have to give them credit for navigating through patent expirations for their best selling drugs. Despite some stumbles (inhibitex acquisition for example), they were able to grow via a nice combination of internal development of assets (e.g. eliquis, sprycel, baraclude - although off patent now, even daclatasvir/asunaprevir which sold an impressive 200M in Japan it's first full quarter) and external acquitision through the medarex deal which was of course huge